- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00655863
Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
SYR-322 (alogliptin) is a selective, orally available inhibitor of dipeptidyl peptidase IV being developed as a treatment for type 2 diabetes mellitus. Dipeptidyl peptidase IV is the primary enzyme involved in the in vivo degradation of at least 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.
Pioglitazone HCl (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan). Pioglitazone HCl depends on the presence of insulin for its mechanism of action.
This study will assess the effects of alogliptin and alogliptin coadministered with pioglitazone HCl on postprandial lipid and lipoprotein metabolism in participants with type 2 diabetes. Individuals who participate in this study will be required to commit to a screening visit and up to 6 additional visits at the study center. Study participation is anticipated to be about 20 weeks (or approximately 5 months). Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, physical examinations and electrocardiograms. At 3 of the visits a meal will be served that must be eaten within 10 minutes.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria
- Diagnosis of type 2 diabetes
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- Either failed treatment with diet and exercise for 3 months prior to Screening or has been receiving a stable dose of metformin, sulfonylurea, nateglinide, or repaglinide for more than 3 months prior to Screening.
- Inadequate glycemic control as defined by glycosylated hemoglobin concentration between 6.5 and 9.0%, inclusive.
- Fasting plasma glucose less than 13.3 mmol per L.
- Fasting serum triglyceride level of 1.7 to 5.0 mmol per L, inclusive.
- Has not been receiving any lipid-lowering therapy within 3 months prior to Screening or on a stable statin and/or ezetimibe therapy (same drug and dose) for at least 3 months.
- Body mass index greater than 23 kg/m2 and less than 45 kg/m2.
- If has regular use of other, non-excluded medications, must be on a stable dose for at least 4 weeks prior to Screening. Use of as needed prescription medications and over-the-counter medications is allowed at the discretion of the investigator.
- Is to be Apolipoprotein E 3/3 or Apolipoprotein E 3/4 phenotype positive prior to baseline.
Exclusion Criteria
- History of type 1 diabetes.
- History of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.
- Diastolic blood pressure greater than 100 mm Hg or a systolic blood pressure of greater than 160 mm Hg.
- History of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study medication.
- Hemoglobin less than 120 g per L for males and less than100 g per L for females.
- Alanine transaminase level greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.
- Serum creatinine level greater than 133 μmol per L.
- Fasting total cholesterol greater than 6.5 mmol per L.
- New York Heart Association heart failure of any Class (I-IV) regardless of therapy.
- History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or myocardial infarction within 6 months prior to Screening.
- History of acute metabolic diabetic complications.
- History of any hemoglobinopathy that may affect determination of glycosylated hemoglobin.
- History of infection with human immunodeficiency virus.
- History of diabetic gastro paresis.
- History of gastric bypass surgery.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Placebo QD
|
Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Autres noms:
|
Expérimental: Alogliptine 25 mg QD
|
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Autres noms:
|
Expérimental: Alogliptin 25 mg QD + Pioglitazone 30 mg QD
|
Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.
Délai: Baseline and Week 16.
|
The change in postprandial (after eating a meal) incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC (0-8h)) postdose at week 16 relative to baseline.
|
Baseline and Week 16.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 4.
Délai: Baseline and Week 4.
|
The change in postprandial incremental area under the plasma concentration-time curve from 0 to 8 hours (AUC(0-8h)) postdose at week 4 relative to baseline.
|
Baseline and Week 4.
|
Change From Baseline in Postprandial Incremental Area Under the Curve Changes for Lipid Parameters.
Délai: Baseline, Week 4 and Week 16.
|
The change in postprandial incremental area under the plasma concentration-time curve for very-low-density lipoprotein (VLDL) cholesterol, VLDL triglycerides, VLDL2 cholesterol, VLDL2 triglycerides, chylomicron cholesterol, chylomicron triglycerides, intermediate-density lipoprotein (IDL) cholesterol, and IDL triglycerides from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Postprandial Incremental Area Under the Curve for Lipoprotein Parameters.
Délai: Baseline, Week 4 and Week 16.
|
Postprandial incremental area under the curve changes for very-low-density lipoprotein (VLDL) Apo B-48, VLDL Apo B 100, VLDL2 Apo B-48, VLDL2 Apo B 100, chylomicron Apo B-48, chylomicron Apo B 100, and intermediate density lipoprotein (IDL) Apo B-48, IDL Apo B 100, and triglyceride-rich remnant (TRR) lipoproteins from 0 to 8 hours postdose at week 4 and week 16 relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Postprandial Changes Over Time From Baseline for Glucagon-like Peptide-1 (GLP-1)
Délai: Baseline, Week 4 and Week 16.
|
Postprandial changes over time at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Postprandial Changes Over Time From Baseline for Glucose
Délai: Baseline, Week 4 and Week 16.
|
Postprandial changes over time at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Postprandial Changes Over Time From Baseline for Insulin
Délai: Baseline, Week 4 and Week 16.
|
Postprandial changes over time at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Postprandial Changes Over Time From Baseline for Glucagon
Délai: Baseline, Week 4 and Week 16.
|
Postprandial changes over time at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Glycosylated Hemoglobin
Délai: Baseline, Week 8 and Week 16.
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.
|
Baseline, Week 8 and Week 16.
|
Change From Baseline in Fasting Plasma Glucose
Délai: Baseline, Week 4, Week 8 and Week 16.
|
The change in fasting plasma glucose collected at each week indicated relative to baseline.
|
Baseline, Week 4, Week 8 and Week 16.
|
Change From Baseline in Postprandial C-Peptide
Délai: Baseline, Week 4 and Week 16.
|
The change in postprandial C-peptide collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Postprandial Proinsulin
Délai: Baseline, Week 4 and Week 16.
|
The change in postprandial proinsulin collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in High-sensitive C-reactive Protein (Hs-CRP)
Délai: Baseline, Week 4 and Week 16.
|
The change in hs-CRP collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Adiponectin
Délai: Baseline, Week 4 and Week 16.
|
The change in adiponectin collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Anti-Vascular Cell Adhesion Molecule (VCAM)
Délai: Baseline, Week 4 and Week 16.
|
The change in VCAM collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Anti-Intercellular Adhesion Molecule (ICAM)
Délai: Baseline, Week 4 and Week 16.
|
The change in ICAM collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in e-Selectin
Délai: Baseline, Week 4 and Week 16.
|
The change in e-Selectin collected at each week indicated relative to baseline.
|
Baseline, Week 4 and Week 16.
|
Change From Baseline in Endothelial Function Through Pulse Wave Tonometry
Délai: Baseline and Week 16.
|
Pulse wave tonometry performed before the meal and 2 hours postmeal using one recording consisting of 15 to 20 sequentially recorded radial artery waveforms collected at each assessment.
|
Baseline and Week 16.
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles du métabolisme du glucose
- Maladies métaboliques
- Maladies du système endocrinien
- Diabète sucré
- Agents hypoglycémiants
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Les hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Inhibiteurs de protéase
- Incrétines
- Inhibiteurs de dipeptidyl-peptidase IV
- Pioglitazone
- Alogliptine
Autres numéros d'identification d'étude
- SYR-322_301
- 2007-000486-38 (Numéro EudraCT)
- U1111-1113-2081 (Identificateur de registre: WHO)
- NL22649.029.08 (Identificateur de registre: CCMO)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
Longeveron Inc.RésiliéSyndrome hypoplasique du cœur gaucheÉtats-Unis